Protagonist Therapeutics, Inc.
(NASDAQ : PTGX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. 1.17%246.351.5%$948.15m
MRNAModerna, Inc. 0.11%142.350.0%$806.78m
REGNRegeneron Pharmaceuticals, Inc. 1.40%602.722.6%$519.19m
VRTXVertex Pharmaceuticals, Inc. 2.17%282.171.9%$512.67m
GILDGilead Sciences, Inc. 0.48%62.511.0%$510.20m
NVAXNovavax, Inc. 1.28%51.7275.7%$422.53m
ILMNIllumina, Inc. -0.88%185.783.3%$354.39m
BIIBBiogen, Inc. 1.35%205.241.8%$245.45m
SNSSSunesis Pharmaceuticals, Inc. 1.80%3.400.7%$237.67m
CRSPCRISPR Therapeutics AG -0.40%63.030.6%$169.22m
BNTXBioNTech SE 0.94%141.140.0%$168.46m
BMRNBioMarin Pharmaceutical, Inc. 0.37%83.464.2%$123.97m
EXASEXACT Sciences Corp. -1.00%40.7017.7%$98.50m
IOVAIovance Biotherapeutics, Inc. -2.14%10.750.0%$93.65m
TECHBio-Techne Corp. -0.18%345.394.5%$93.05m

Company Profile

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.